Promising drug shows hope for Hard-to-Treat prostate cancer
NCT ID NCT04288687
First seen Mar 12, 2026 · Last updated May 22, 2026 · Updated 10 times
Summary
This study tested a drug called niraparib in 11 men with advanced prostate cancer that was growing despite hormone therapy. All participants had previously received platinum chemotherapy. The goal was to see if niraparib could keep the cancer from progressing for at least 6 months. The trial focused on men whose tumors had specific DNA repair defects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.